GGH
ADCT icon

GCM Grosvenor Holdings’s ADC Therapeutics ADCT Stock Holding History

GCM Grosvenor Holdings’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-410,888
Closed -$1.29M – 19
2024
Q3 		$1.29M Hold
410,888
– – 0.2% 21
2024
Q2 		$1.3M Hold
410,888
– – 0.19% 20
2024
Q1 		$1.84M Hold
410,888
– – 0.28% 19
2023
Q4 		$682K Hold
410,888
– – 0.12% 18
2023
Q3 		$369K Hold
410,888
– – 0.07% 16
2023
Q2 		$883K Hold
410,888
– – 0.38% 15
2023
Q1 		$801K Sell
410,888
-324,583
-44% -$1.2M 0.22% 17
2022
Q4 		$2.82M Hold
735,471
– – 0.72% 16
2022
Q3 		$3.54M Sell
735,471
-562,541
-43% -$4.07M 0.84% 12
2022
Q2 		$10.3M Buy
+1,298,012
New +$12.3M 2.33% 12

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM Grosvenor Holdings's ADCT Position: Q4 2024 in Review

GCM Grosvenor Holdings sold out of ADC Therapeutics (ADCT) in Q4 2024, closing a stake of 410,888 shares — an estimated $1.29M sold.

GCM Grosvenor Holdings first reported a position in ADCT in Q2 2022 and held it in 10 quarters. The position peaked at $10.3M in Q2 2022. 83 funds tracked by Wall St. Rank hold ADCT as of Q4 2024.

  • GCM Grosvenor Holdings reported no remaining ADC Therapeutics position as of Q4 2024 after selling out during the quarter.
  • GCM Grosvenor Holdings sold 410,888 ADC Therapeutics shares in Q4 2024, an estimated $1.29M.
  • GCM Grosvenor Holdings first reported a position in ADC Therapeutics in Q2 2022 and held it in 10 quarters.
  • GCM Grosvenor Holdings's ADC Therapeutics position peaked at $10.3M in Q2 2022.
  • 83 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2024.

Based on GCM Grosvenor Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.